EGFR and rectal cancer: Spindler et al. [48] studied a SNP in the Sp1 binding site of the EGFR promoter (Sp1-216 G/T), which has been associated with higher gene expression, in a group of patients with locally advanced rectal cancer; patients with T variants had a better possibility of pCR than GG homozygous patients (65% for G/T and T/T vs. 34% for GG).